Estimating the cost-effectiveness of HIV prevention programmes in Vietnam, 2006-2010: A modelling study

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Pham, Quang Duy ^a,b   Wilson, David P ^a   Kerr, Cliff C ^a   Shattock, Andrew J ^a   Do, Hoa Mai ^c   Duong, Anh Thuy ^d   Nguyen, Long Thanh ^d   Zhang, Lei ^a,e,f  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b PASTEUR INSTITUTE   (Viet Nam)

^c HANOI UNIVERSITY OF PUBLIC HEALTH   (Viet Nam)

^d Department of Planning and Finance Vietnam Administration of HIV/AIDS Control ^*  (Viet Nam)

^e MONASH UNIVERSITY   (Australia)

^f MELBOURNE SEXUAL HEALTH CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; CONDOM USE; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DATA SYNTHESIS; DEATH; DISABILITY ADJUSTED LIFE YEAR; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INFECTION PREVENTION; MATHEMATICAL MODEL; MEN WHO HAVE SEX WITH MEN; NAMED GROUPS OF PERSONS; PEOPLE WHO INJECT DRUG; PREVALENCE; PROGRAM COST EFFECTIVENESS; PROSTITUTION; QUALITY OF LIFE; VIET NAM; VIRUS TRANSMISSION; COST BENEFIT ANALYSIS; ECONOMICS; HIV INFECTIONS; ORGANIZATION AND MANAGEMENT; PRIMARY PREVENTION; PUBLIC HEALTH; STATISTICAL MODEL;

COST-BENEFIT ANALYSIS; HIV INFECTIONS; HUMANS; MODELS, STATISTICAL; NATIONAL HEALTH PROGRAMS; PRIMARY PREVENTION; VIETNAM;

EID: 84941272709     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0133171     Document Type: Article

References (48)

1. Quan VM, Chung A, Abdul-Quader AS. The feasibility of a syringe-needle-exchange program in Vietnam. Subst Use Misuse. 1998; 33(5):1055-67. PMID: 9596375.
2. Quan VM, Chung A, Long HT, Dondero TJ. HIV in Vietnam: The evolving epidemic and the prevention response, 1996 through 1999. J Acquir Immune Defic Syndr. 2000; 25(4):360-9. PMID: 11114837.
3. Hien NT, Long NT, Huan TQ. HIV/AIDS epidemics in Vietnam: Evolution and responses. AIDS Educ Prev. 2004; 16(Suppl A):137-54.
4. Vuong T, Ali R, Baldwin S, Mills S. Drug policy in Vietnam: A decade of change? Int J Drug Policy. 2012; 23(4):319-26. doi:10.1016/j.drugpo.2011.11.005 PMID: 22206713.
5. Srikantiah P, Ghidinelli M, Bachani D, Chasombat S, Daoni E, Mustikawati DE, et al. Scale-up of national antiretroviral therapy programs: progress and challenges in the Asia Pacific region. AIDS. 2010; 24:S62-S71. PMID: 20926930.
6. The Joint United Nations Programme on HIV/AIDS (UNAIDS). Vietnam national AIDS spending assessment, 2008-2010. Hanoi, Vietnam: UNAIDS; 2012. Available at: http://www.aidsdatahub.org/vietnam-national-aids-spending-assessment-2008-2010-unaids-2012. Accessed 25 July 2012. 2012.
7. Kato M, Granich R, Bui DD, Tran HV, Nadol P, Jacka D, et al. The potential impact of expanding antiretroviral therapy and combination prevention in Vietnam: Towards elimination of HIV transmission. J Acquir Immune Defic Syndr. 2013; 63(5):e142-e9. PMID: 23714739.
8. Tran BX, Ohinmaa A, Duong AT, Nguyen LT, Vu PX, Mills S, et al. The cost-effectiveness and budget impact of Vietnam's methadone maintenance treatment programme in HIV prevention and treatment among injection drug users. Glob Public Health. 2012; 7(10):1080-94. doi:10.1080/17441692.2012.736259 PMID: 23106230.
9. Tran BX, Ohinmaa A, Duong AT, Nguyen LT, Vu PX, Mills S, et al. Cost-effectiveness of integrating methadone maintenance and antiretroviral treatment for HIV-positive drug users in Vietnam's injectiondriven HIV epidemics. Drug Alcohol Depend. 2012; 125(3):260-6. doi:10.1016/j.drugalcdep.2012.02.021 PMID: 22436971.
10. Tran DA, Wilson DP, Shakeshaft A, Ngo AD, Reyes J, Doran C, et al. Cost-effectiveness of antiretroviral therapy expansion strategies in Vietnam. AIDS Patient Care STDS. 2014; 28(7):365-71. doi:10.1089/apc.2014.0016 PMID: 24983389.
11. National AIDS Standing Bureau, Family Health International, United States Agency for International Development. HIV/AIDS behavioral surveillance survey Vietnam 2000. Hanoi, Vietnam; 2001. Available at: http://www.aidsdatahub.org/behavioral-surveillance-survey-vietnam-2000-bss-round-1-results-national-aids-standing-bureau-fhi-usaid-et-al-2000. Accessed 25 July 2012.
12. Ministry of Health. Results from the HIV/STI integrated biological and behavioral surveillance (IBBS) in Vietnam, 2005-2006. Ha Noi, Vietnam: Ministry of Health; 2006. Available at: http://www.inthealth.ku.dk/reach/resources/surveillance.pdf/. Accessed 15 April 2014.
13. Ministry of Health. Results from the HIV/STI intergrated biological and behavioral surveillance (IBBS) in Vietnam round II, 2009. Hanoi, Vietnam: Ministry of Health; 2011. Available at: http://aidsdatahub.org/dmdocuments/Vietnam-IBBS-Round-II-2009.pdf. Accessed 22 September 2011.
14. Family Health International. Cost analyses of selected USAID-supported HIV interventions managed by FHI 360 in Vietnam: outreach, HIV testing and counseling (HTC), and anti-retroviral treatment (ART) 2009-2010. Hanoi, Vietnam, 2012: FHI 360/Urban Care.
15. Duong AT, Kato M, Bales S, Do NT, Minh Nguyen TT, Thanh Cao TT, et al. Costing analysis of national HIV treatment and care program in Vietnam. J Acquir Immune Defic Syndr. 2014; 65(1):e1-e7. PMID: 23846564.
16. Kerr CC, Stuart RM, Gray RT, Shattock A, Fraser N, Benedikt C, et al. Optima: A model for HIV epidemic analysis, program prioritization, and resource optimization. J Acquir Immune Defic Syndr.2015; 69(3):365-76.
17. RØTtingen J-A, Garnett GP. The epidemiological and control implications of HIV transmission probabilities within partnerships. Sex Transm Dis. 2002; 29(12):818-27. PMID: 12466726.
18. Patel P, Borkowf CB, Brooks JT, Lasry A, Lansky A, Mermin J. Estimating per-act HIV transmission risk: A systematic review. AIDS. 2014; 28(10):1509-19. PMID: 24809629.
19. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011; 365(6):493-505. doi:10.1056/NEJMoa1105243 PMID: 21767103.
20. Wilson DP, Law MG, Grulich AE, Cooper DA, Kaldor JM. Relation between HIV viral load and infectiousness: A model-based analysis. Lancet. 2008; 372(9635):314-20. doi:10.1016/S0140-6736(08)61115-0 PMID: 18657710.
21. Salomon JA, Vos T, Hogan DR, Gagnon M, Naghavi M, Mokdad A, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859):2129-43. doi:10.1016/S0140-6736(12)61680-8 PMID: 23245605.
22. Stouthard MEA, Essink-Bot M-L, Bonsel GJ, on behalf of the DDWG. Disability weights for diseases: A modified protocol and results for a Western European region. Eur J Public Health. 2000; 10(1):24-30.
23. The Joint United Nations Programme on HIV/AIDS (UNAIDS). HIV in Asia and the Pacific UNAIDS report 2013. Bangkok, Thailand: UNAIDS's Regional Support Team for Asia and the Pacific; 2013. Available at: http://www.aidsdatahub.org/HIV-in-Asia-and-the-Pacific-UNAIDS-Report-2013. Accessed 20 June 2014.
24. Shillcutt S, Walker D, Goodman C, Mills A. Cost effectiveness in low- And middle-income countries. Pharmacoeconomics. 2009; 27(11):903-17. doi:10.2165/10899580-000000000-00000 PMID: 19888791.
25. Prinja S, Bahuguna P, Rudra S, Gupta I, Kaur M, Mehendale SM, et al. Cost effectiveness of targeted HIV prevention interventions for female sex workers in India. Sex Transm Infect. 2011; 87(4):354-61. doi:10.1136/sti.2010.047829 PMID: 21447514.
26. Hogan DR, Baltussen R, Hayashi C, Lauer JA, Salomon JA. Achieving the millennium development goals for health: cost effectiveness analysis of strategies to combat HIV/AIDS in developing countries. BMJ. 2005; 331(7530):1431-5. PMID: 16282380.
27. Aspinall EJ, Nambiar D, Goldberg DJ, Hickman M, Weir A, Van-Velzen E, et al. Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: A systematic review and meta-analysis. Int J Epidemiol. 2013; 43(1):235-48. doi:10.1093/ije/dyt243 PMID: 24374889.
28. Iversen J, Chow S, Maher L. Australian needle and syringe program survey: national data report, 2009-2013. The Kirby Institute, UNSW Australia, 2014. Available at: http://www.kirby.unsw.edu.au/surveillance/Australian-NSP-Survey-Data-Reports. Accessed 30 June 2014.
29. Public Health Agency of Canada. I-Track: Enhanced surveillance of risk behaviours among injecting drug users in Canada. Phase I Report, August 2006. Surveillance and Risk Assessment Division, Centre for Infectious Disease Prevention and Control, Public Heath Agency of Canada, 2006. Available at: Www.phac-aspc.gc.ca/i-track/sr-re-1/index-eng.php. Accessed 30 June 2014.
30. Vickerman P, Kumaranayake L, Balakireva O, Guinness L, Artyukh O, Semikop T, et al. The cost-effectiveness of expanding harm reduction activities for injecting drug users in Odessa, Ukraine. Sex Transm Dis. 2006; 33(10):S89-S102. PMID: 16735956.
31. Guinness L, Vickerman P, Quayyum Z, Foss A, Watts C, Rodericks A, et al. The cost-effectiveness of consistent and early intervention of harm reduction for injecting drug users in Bangladesh. Addiction. 2010; 105(2):319-28. doi:10.1111/j.1360-0443.2009.02755.x PMID: 19922513.
32. Zhang L, Yap L, Xun Z, Wu Z, Wilson D. Needle and syringe programs in Yunnan, China yield health and financial return. BMC Public Health. 2011; 11(1):250.
33. Kumaranayake L, Vickerman P, Walker D, Samoshkin S, Romantzov V, Emelyanova Z, et al. The costeffectiveness of HIV preventive measures among injecting drug users in Svetlogorsk, Belarus. Addiction. 2004; 99(12):1565-76. PMID: 15585048.
34. Nguyen TTM, Nguyen LT, Pham MD, Vu HH, Mulvey KP. Methadone maintenance therapy in Vietnam: An overview and scaling-up plan. Adv Prev Med. 2012.
35. Wammes JJG, Siregar AY, Hidayat T, Raya RP, van Crevel R, van der Ven AJ, et al. Cost-effectiveness of methadone maintenance therapy as HIV prevention in an Indonesian high-prevalence setting: A mathematical modeling study. Int J Drug Policy. 2012; 23(5):358-64. doi:10.1016/j.drugpo.2012.06.009 PMID: 22884538.
36. Marsch LA. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: A meta-analysis. Addiction. 1998; 93(4):515-32. PMID: 9684390.
37. Van Den Berg C, Smit C, Van Brussel G, Coutinho R, Prins M. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: Evidence from the Amsterdam Cohort Studies among drug users. Addiction. 2007; 102(9):1454-62. PMID: 17697278.
38. Beyrer C, Baral SD, van Griensven F, Goodreau SM, Chariyalertsak S, Wirtz AL, et al. Global epidemiology of HIV infection in men who have sex with men. Lancet. 2012; 380(9839):367-77. doi:10.1016/S0140-6736(12)60821-6 PMID: 22819660.
39. Pham QD, Nguyen TV, Hoang CQ, Cao V, Khuu NV, Phan HTT, et al. Prevalence of HIV/STIs and associated factors among men who have sex with men in An Giang, Vietnam. Sex Transm Dis. 2012; 39(10):799-806. PMID: 23001268.
40. Gilks CF, Crowley S, Ekpini R, Gove S, Perriens J, Souteyrand Y, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet. 2006; 368 (9534):505-10. PMID: 16890837.
41. Easterbrook PJ, Irvine CJ, Vitoria M, Shaffer N, Muhe LM, Negussie EK, et al. Developing the 2013 WHO consolidated antiretroviral guidelines. AIDS. 2014; 28:S93-S100. PMID: 24849484.
42. Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Cori A, et al. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: A combined analysis of 12 mathematical models. Lancet Glob Health. 2014; 2(1):e23-e34. doi:10.1016/S2214-109X(13)70172-4 PMID: 25104632.
43. Family Health International. Improving the HIV cascade of services in Vietnam. ICAAP, Bangkok, Thailand, November 2013: Family Health International. Available at: http://www.slideshare.net/scfhi/improving-the-hiv-cascade-of-services-in-vietnam. Accessed 20 July 2014.
44. Vassall A, Pickles M, Chandrashekar S, Boily M-C, Shetty G, Guinness L, et al. Cost-effectiveness of HIV prevention for high-risk groups at scale: An economic evaluation of the Avahan programme in south India. Lancet Glob Health. 2014; 2(9):e531-e40. doi:10.1016/S2214-109X(14)70277-3PMID: 25304420.
45. Craig AP, Thein HH, Zhang L, Gray RT, Henderson K, Wilson D, et al. Spending of HIV resources in Asia and Eastern Europe: systematic review reveals the need to shift funding allocations towards priority populations. J Int AIDS Soc. 2014; 17(1):188822.
46. Jia Z, Mao Y, Zhang F, Ruan Y, Ma Y, Li J, et al. Antiretroviral therapy to prevent HIV transmission in serodiscordant couples in China (2003-11): A national observational cohort study. Lancet. 2013; 382 (9899):1195-203. doi:10.1016/S0140-6736(12)61898-4 PMID: 23206835.
47. Birungi J, Wang H, Ngolobe MH, Muldoon K, Khanakwa S, King R, et al. Lack of effectiveness of antiretroviral therapy (ART) as an HIV prevention tool for serodiscordant couples in a rural ART program without viral load monitoring in Uganda [abstract no. TUAC0103]. Presented at: 19th International AIDS Conference, Washington, USA, July 2012. Available from: http://www.iasociety.org/Abstracts/A200745964.aspx. Accessed 13 August 2014.
48. Nguyen DB, Do NT, Shiraishi RW, Le YN, Tran QH, Huu Nguyen H, et al. Outcomes of antiretroviral therapy in Vietnam: Results from a national evaluation. PLoS One. 2013; 8(2):e55750. doi:10.1371/journal.pone.0055750 PMID: 23457477.